Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

3.000 -0.030 (-0.99%)
Streaming Delayed Price Updated: 12:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Cp

< Previous 1 2 3 4 Next >
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Biopharma's Return On Capital Employed Insights
 
Via Benzinga
Recap: Arbutus Biopharma Q2 Earnings
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Biopharma: Q1 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via Globe NewsWire
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
 
Via Benzinga
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via Globe NewsWire
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via Globe NewsWire
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive 
Via Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.